<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Endocrinology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1664-2392</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25120531</article-id>
      <article-id pub-id-type="pmc">4110518</article-id>
      <article-id pub-id-type="doi">10.3389/fendo.2014.00124</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Endocrinology</subject>
          <subj-group>
            <subject>Mini Review</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Estrogens and Stem Cells in Thyroid Cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zane</surname>
            <given-names>Mariangela</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn001">
            <sup>&#x2020;</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/161757"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Catalano</surname>
            <given-names>Veronica</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn001">
            <sup>&#x2020;</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/168797"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Scavo</surname>
            <given-names>Emanuela</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/167182"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bonanno</surname>
            <given-names>Marco</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/173929"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pelizzo</surname>
            <given-names>Maria Rosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/168137"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Todaro</surname>
            <given-names>Matilde</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/173945"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stassi</surname>
            <given-names>Giorgio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/27755"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>1</sup><institution>Department of Surgical and Oncological Sciences, University of Palermo</institution>, <addr-line>Palermo</addr-line>, <country>Italy</country></aff>
      <aff id="aff2"><sup>2</sup><institution>Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua</institution>, <addr-line>Padua</addr-line>, <country>Italy</country></aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Terry Francis Davies, Icahn School of Medicine at Mount Sinai, USA</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Carmelo Nucera, Harvard Medical School, USA; Antonio Di Cristofano, Albert Einstein College of Medicine, USA</p>
        </fn>
        <corresp content-type="corresp" id="cor1">*Correspondence: Giorgio Stassi, Laboratory of Cellular and Molecular Pathophysiology, Department of Surgical and Oncological Sciences, University of Palermo, Via Liborio Giuffr&#xE8; 5, Palermo 90127, Italy e-mail: <email>giorgio.stassi@unipa.it</email></corresp>
        <fn fn-type="other" id="fn001">
          <p><sup>&#x2020;</sup>Mariangela Zane and Veronica Catalano have contributed equally to this work.</p>
        </fn>
        <fn fn-type="other" id="fn002">
          <p>This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>5</volume>
      <elocation-id>124</elocation-id>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Zane, Catalano, Scavo, Bonanno, Pelizzo, Todaro and Stassi.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Recent discoveries highlight the emerging role of estrogens in the initiation and progression of different malignancies through their interaction with stem cell (SC) compartment. Estrogens play a relevant role especially for those tumors bearing a gender disparity in incidence and aggressiveness, as occurs for most thyroid diseases. Although several experimental lines suggest that estrogens promote thyroid cell proliferation and invasion, their precise contribution in SC compartment still remains unclear. This review underlines the interplay between hormones and thyroid function, which could help to complete the puzzle of gender discrepancy in thyroid malignancies. Defining the association between estrogen receptors&#x2019; status and signaling pathways by which estrogens exert their effects on thyroid cells is a potential tool that provides important insights in pathogenetic mechanisms of thyroid tumors.</p>
      </abstract>
      <kwd-group>
        <kwd>thyroid cancer</kwd>
        <kwd>stem cells</kwd>
        <kwd>cancer stem cells</kwd>
        <kwd>estrogens</kwd>
        <kwd>thyroid hormones</kwd>
        <kwd>growth factors</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="99"/>
        <page-count count="8"/>
        <word-count count="6425"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="S1">
      <title>Introduction</title>
      <p>The endocrine system consists of a network of glands secreting hormones, which are chemical messengers that cooperate in growth, development, metabolism, and reproductive functions. The largest endocrine organ in the human body is the thyroid gland, whose function is the systemic metabolic regulation through thyroid hormones (THs) produced by follicular cells, and calcitonin produced by parafollicular cells. Different malignancy histotypes can arise from these cells: papillary (PTC), follicular (FTC), and anaplastic thyroid carcinomas (ATC) originate from follicular cells, while medullary thyroid carcinomas (MTC) derive from parafollicular cells (<xref rid="B1" ref-type="bibr">1</xref>). Notably, more than 95% of thyroid carcinomas (TCs) arise from follicular cells. These malignancies are indolent tumors treated by surgical resection with or without radioactive-iodine ablation since they maintain their distinct potential to concentrate Iodine. The loss of typical thyroid cell characteristics and functions, including expression of the thyroid-stimulating hormone (TSH) receptor (TSH-R), thyroglobulin (Tg), thyroid peroxidase (TPO), and sodium iodide symporter (NIS), defines the hallmark of ATCs, which are lethal malignancies with no effective therapy (<xref rid="B1" ref-type="bibr">1</xref>&#x2013;<xref rid="B3" ref-type="bibr">3</xref>).</p>
      <p>Besides genetic alterations in mitogen-activated protein kinase (MAPK), PI-3 kinase (PI3K), and TSH signaling pathways, thyroid carcinogenesis is fostered by the microenvironment, growth factors (GFs), and various hormones, including estrogens (<xref rid="B4" ref-type="bibr">4</xref>). Hormones can set off a cascade of signaling pathways, enhancing or contrasting specific effects triggered by other factors. Based on this <italic>scenario</italic>, the role of estrogens has been proposed in the pathogenesis of thyroid proliferative and neoplastic disorders. This hypothesis is supported by data regarding gender incidence, which reported a frequency of thyroid nodules about three to four times higher in women than in men with a peak rate occurring earlier in women (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Furthermore, the clarification of the estrogen-driven pathogenesis could be crucial in explaining why PTC constitutes the seventh most common cancer in the female gender (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). An <italic>in vivo</italic> study reported that circulating estrogens are directly responsible for the increased female susceptibility to thyroid disease, through PI3K pathway activation and repressing p27 expression. The authors also observed a significant estrogen role in the transcriptional regulation of TPO, DUOX1, and NIS genes (<xref rid="B9" ref-type="bibr">9</xref>). Although several studies have demonstrated a direct action by estrogens on thyroid growth and function (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>&#x2013;<xref rid="B12" ref-type="bibr">12</xref>), the precise mechanism underlying the proliferative and neoplastic disorders still remains undefined. In particular, it would be interesting to explore the role of hormones in TC initiation.</p>
      <p>The cellular origin of TCs has been explained by different models (Figure <xref ref-type="fig" rid="F1">1</xref>). The multistep carcinogenesis model predicts that TC originates from follicular cells as a consequence of multiple mutations accumulated throughout their life-span. These events are characterized by a dedifferentiation process with a marked epithelial-to-mesenchymal transition (EMT), in which well-differentiated TC cells transform into a more undifferentiated phenotype (<xref rid="B1" ref-type="bibr">1</xref>). The fetal cell carcinogenesis model hypothesizes that TC cells would be generated by transforming three types of fetal thyroid cells, stem cells (SCs), thyroblasts, and prothyrocytes, which result in ATC, PTC, and FTC, respectively (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). The heterogeneity of tumor bulk had led to a cancer stem cells (CSCs) model to propose TC as an SC disease. The growing body of experimental evidence has revealed that an accumulation of genetic abnormalities in tissue-resident SCs or in their more committed progenies, concomitant with the niche epigenetic alterations, result in their malignant transformation (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>The cellular origin of thyroid carcinomas is shown</bold>. According to the multistep carcinogenesis model, TC originates from follicular cells as a consequence of multiple mutations accumulated throughout their life-span. Thyrocytes could give rise to PTC by RAS and BRAF mutations or RET/PTC and NTRK1 rearrangements and to FTC by point mutations of the RAS gene and PAX8/PPAR&#x3B3; rearrangement. ATC derive from PTC and FTC after deregulation of the p53 and the Wnt/&#x3B2;-catenin pathway. In fetal cell carcinogenesis model, three types of fetal thyroid cells were proposed to generate different forms of thyroid cancer. Fetal thyroid stem cells, characterized by expression of the oncofetal fibronectin (OF), generate ATC, thyroblasts, which express OF and the differentiation marker Tg, are proposed to be the cellular origin of PTC. The more differentiated prothyrocytes, expressing Tg, give rise to FTC. The cancer stem cells model proposes TC as an SC disease. The accumulation of mutations in differentiated thyrocytes leads to their transformation. A subset of these cells may (in more aggressive tumor types) dedifferentiate and assume CSC characteristics.</p>
        </caption>
        <graphic xlink:href="fendo-05-00124-g001"/>
      </fig>
      <p>The &#x201C;cell-of-origin&#x201D; concept explains how a normal cell acquires the first alteration able to trigger tumor initiation (tumor-initiating cells, TICs) (<xref rid="B17" ref-type="bibr">17</xref>). Wnt pathway plays a crucial role in SC/progenitor compartment maintenance, and has been described in several tumors, including TC, resulting in nuclear &#x3B2;-catenin-induced proliferation (<xref rid="B18" ref-type="bibr">18</xref>&#x2013;<xref rid="B20" ref-type="bibr">20</xref>).</p>
      <p>In this review, the most current findings supporting the carcinogenesis effects of estrogens and THs will be addressed. A special emphasis will be given to the role of exogenous and endogenous GFs affecting thyroid proliferative pathways in SC compartment.</p>
    </sec>
    <sec id="S2">
      <title>Estrogens</title>
      <p>As recently published by Morrison&#x2019;s research group, estrogens are involved in increasing hematopoietic SC self-renewal in female subjects and more specifically during pregnancy (<xref rid="B21" ref-type="bibr">21</xref>). It is likely that normal and tumor thyroid tissues, which express estrogen receptors (ER), could be subject to the same mechanism of estrogen action (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B22" ref-type="bibr">22</xref>&#x2013;<xref rid="B24" ref-type="bibr">24</xref>).</p>
      <p>Involved in cellular processes such as growth, cell motility, and apoptosis, in reproductive tissues and other organs, including endocrine glands, estrogens are mainly produced by the adrenal cortex and ovary, but also by the thyroid (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). They are present in women and men with a notable increase in women at reproductive age. The three principal estrogens, estrone (E1), estradiol (E2), and estriol (E3), are processed in metabolites with different estrogenic abilities, which create a different risk in developing cancer (<xref rid="B27" ref-type="bibr">27</xref>&#x2013;<xref rid="B29" ref-type="bibr">29</xref>).</p>
      <p>Estradiol is the most potent estrogen since it has the highest affinity to its receptors. Estrogens perform their function by binding to ER alpha and beta (ER-&#x3B1;, ER-&#x3B2;), and a transmembrane intracellular non-classical ER G-protein-coupled receptor 30 (GPR30) (Figure <xref ref-type="fig" rid="F2">2</xref>). ER-&#x3B1; and ER-&#x3B2; are soluble intracellular nuclear receptors, belonging to a ligand-dependent nuclear receptor superfamily of transcription factors (TFs) (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). ER-&#x3B1; is the key factor of E2-induced proliferation with an anti-apoptosis effect. In females of reproductive age, ER-&#x3B1; levels are higher in PTC compared to nodular goiter patients, showing a positive correlation between ER-&#x3B1; and Ki-67 expression levels. In contrast, ER-&#x3B2; is associated with apoptosis and growth inhibition, providing a negative correlation with mutant P53 (<xref rid="B30" ref-type="bibr">30</xref>). PPAR&#x3B3; also interacts with ER-&#x3B1; inhibiting each other, and with ER-&#x3B2; enhancing their inhibitory effect on cell proliferation and migration (<xref rid="B31" ref-type="bibr">31</xref>). In light of this, the ER-&#x3B1;/ER-&#x3B2; <italic>ratio</italic> could be helpful to elucidate the TC pathophysiology (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B32" ref-type="bibr">32</xref>).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Signaling pathways in follicular cells are shown</bold>. The main regulators of thyroid proliferation and function act through TSH signaling and GF pathway. THs control the secretion of TSH, which binds to TSH-R and induces the coupling of G-proteins stimulating AC and PLC. TSH also acts via PI3K pathway. GFs act via MAPK and PI3K pathways regulating the expression of genes involved in survival, cell cycle progression, and proliferation. Estrogens regulate proliferation, cell motility, differentiation, and apoptosis through four different mechanisms: (1) <italic>genomic (or classical) estrogen-signaling</italic>: E2&#x2013;ER complex translocates into the nucleus, where it binds to ERE-sequences; (2) <italic>ERE-independent genomic actions (TFs cross-talk)</italic>: genes lacking in ERE-sequences are activated by other TFs in the nucleus through protein&#x2013;protein interactions; (3) <italic>non-genomic (or membrane-initiated) estrogen-signaling</italic>: E2 activation of plasma membrane-associated ER and GPR30 trigger the activation of MAPK and PI3K pathways and/or increases the Ca<sup>2+</sup> levels; (4) <italic>ligand-independent signaling</italic>: in absence of E2, GFs can stimulate ERs directly or indirectly through MAPK and/or PI3K pathways. THs play a critical role in development and homeostasis. Nuclear TRs activate gene expression by binding to RXR, which in turn bind to TRE-sequences. Given that EREs share a similar nucleotide sequence with TREs, ERs and TRs can interact and regulate several transcriptional responses. The cross-talk between genomic and non-genomic pathways and other integrative signaling lead to a synergic cell response.</p>
        </caption>
        <graphic xlink:href="fendo-05-00124-g002"/>
      </fig>
      <p>The interaction between estrogens and ERs signals through different pathways:
<list list-type="bullet"><list-item><p>Genomic (or classical) estrogen-signaling: after accessing the cell through passive diffusion, E2 binds to ER, which changes its conformation and homo- or heterodimerizes (E2&#x2013;ER). This complex translocates into the nucleus, where it binds to the 15-bp palindromic estrogen response element (ERE) located in the regulatory regions of target genes. This interaction leads to a co-activators recruitment, which in turn allows expression of genes involved in proliferation (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>).</p></list-item><list-item><p>Estrogen response element-independent genomic actions (TFs cross-talk): ERE-lacking genes can be activated by modulating other TFs through protein&#x2013;protein interactions. This molecular mechanism induces chromatin remodeling, histone unwinding, and interaction with the basal transcription machinery complex (<xref rid="B35" ref-type="bibr">35</xref>&#x2013;<xref rid="B37" ref-type="bibr">37</xref>).</p></list-item><list-item><p>Non-genomic (or membrane-initiated) estrogen-signaling: E2 activation of plasma membrane-associated ER and GPR30 promotes the MAPK and PI3K signaling pathways and/or increases the Ca<sup>2+</sup> levels (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B38" ref-type="bibr">38</xref>&#x2013;<xref rid="B40" ref-type="bibr">40</xref>). They can also activate G-proteins resulting in cAMP production, similar to TSH signaling in thyrocytes, and assist the activation of metalloproteinases (MMPs) and the GF pathway (<xref rid="B5" ref-type="bibr">5</xref>).</p></list-item><list-item><p>Ligand-independent signaling: in absence of E2, GFs can stimulate ERs directly or indirectly through MAPK and/or PI3K pathways (<xref rid="B41" ref-type="bibr">41</xref>).</p></list-item></list></p>
      <p>The cross-talk between genomic and non-genomic pathways, as well as the integrative signaling by E2 in different cell compartments, leads to a synergy that provides plasticity in cell response. Estrogens dispatch their proliferative role also by increasing T<sub>3</sub> levels and stimulating the iodine-uptake and TPO activity (<xref rid="B42" ref-type="bibr">42</xref>).</p>
      <p>Furlanetto et al. (<xref rid="B43" ref-type="bibr">43</xref>) reported that E2 increases proliferation of thyroid cells down-regulating NIS. These data underline the pivotal role of estrogens in the SC compartment maintenance. In normal and tumor thyroid cell lines, Rajoria et al. documented that E2 is associated with increased proliferation, adhesion, invasion, and migration via &#x3B2;-catenin (<xref rid="B7" ref-type="bibr">7</xref>) and MMP-9 modulation (<xref rid="B44" ref-type="bibr">44</xref>). Likewise, E-cadherin down-regulation and &#x3B2;-catenin translocation sustain the metastatic activity of TC cells (<xref rid="B24" ref-type="bibr">24</xref>). These results confirmed the findings by Kouzmenko et al., which reported the first evidence of cross-talk between estrogens and Wnt pathways through functional interaction of &#x3B2;-catenin with ER-&#x3B1; (<xref rid="B45" ref-type="bibr">45</xref>).</p>
      <p>Xu et al. (<xref rid="B8" ref-type="bibr">8</xref>) analyzed whether differentiated and SC/progenitors could be target of estrogen action in thyroid. SCs isolated from goiter tissue enhanced their sphere-forming ability in presence of E2. Moreover, thyroid-sphere cells showed ER-&#x3B1; mRNA levels eight times higher than those of more differentiated thyrocytes. This suggests the gender discrepancy in TC incidence and a difference in terms of aggressiveness and survival.</p>
    </sec>
    <sec id="S3">
      <title>Thyroid Hormones</title>
      <p>Thyroid hormones control the secretion of thyrotropin-releasing hormone (TRH) from the hypothalamus and TSH from the anterior pituitary through negative feedback loops (<xref rid="B1" ref-type="bibr">1</xref>). Thyroid homeostasis and function are regulated by a concert of signals accumulated from TSH and GF pathways. TSH binds to TSH-R and induces the coupling of different G-proteins, stimulating adenylate cyclase (AC) and phospholipase C (PLC) (Figure <xref ref-type="fig" rid="F2">2</xref>). This promotes iodide uptake and TG, TPO, and NIS expression, producing thyroxine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>) (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B46" ref-type="bibr">46</xref>). On the contrary, intracellular Ca<sup>2+</sup> and PLC regulate iodine release, H<sub>2</sub>O<sub>2</sub> production, and Tg iodination (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Although cAMP is the main mediator of TSH stimulation in thyroid cell growth, TSH via PI3K increases cyclin E levels leading to cell cycle progression (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). TSH-R is also associated to the MAPK pathway through its desensitization and internalization apparatus (<xref rid="B51" ref-type="bibr">51</xref>).</p>
      <p>Gain-of-function mutations in TSH-R or Gs genes result in increased cAMP accumulation and TSH-independent proliferation, which account for hyperfunctioning nodules in patients with multinodular goiters (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>). These alterations result insufficient for the malignant transformation of thyroid cells (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Hence, it is likely that other factors intervene in the SC compartment, which is assumed to be the target of neoplastic transformation. Alterations of the Wnt pathway effectors are involved in cancer initiation and progression (<xref rid="B56" ref-type="bibr">56</xref>). In particular, TSH-mediated Wnt-1 over-expression and GSK-3&#x3B2; inhibition promote thyroid cell proliferation (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>).</p>
      <p>Thyroid hormones play a critical role in the tissue development and homeostasis by direct transcriptional regulation or modulation of different pathways (<xref rid="B59" ref-type="bibr">59</xref>). Although T<sub>4</sub> is the predominant hormone produced by the thyroid, T<sub>3</sub> is the active form that mediates gene regulation binding with a higher affinity to thyroid receptors (TRs) (<xref rid="B60" ref-type="bibr">60</xref>). Nuclear TRs activate gene expression by binding with the retinoid X receptors (RXRs) to TH response elements (TRE), located on the promoters of target genes (Figure <xref ref-type="fig" rid="F2">2</xref>) (<xref rid="B61" ref-type="bibr">61</xref>). Given that EREs share a similar nucleotide sequence with TREs, ERs and TRs can interact and regulate several transcriptional responses to environmental <italic>stimuli</italic> (<xref rid="B5" ref-type="bibr">5</xref>). Interestingly, ERE can act as a peroxisome proliferator responsive elements (PPRE), binding PPAR&#x3B3;/RXR. It can henceforth inhibit ER transactivation through a competition for ERE binding (<xref rid="B62" ref-type="bibr">62</xref>). In line with this cross-interaction, the proliferative effect of estrogens on human NPA-87-1 PTC cell line is TSH-independent (<xref rid="B63" ref-type="bibr">63</xref>). Lima et al. demonstrated a more direct proliferative effect since E2 administration to prepubertal and adult rats enhances thyroid weight without significant changes in T<sub>3</sub>, T<sub>4</sub>, and TSH hematopoietic levels (<xref rid="B42" ref-type="bibr">42</xref>).</p>
      <p>Recent studies in human cancers and mouse models provide strong evidence that the loss of TRs function contributes to cancer initiation and progression (<xref rid="B64" ref-type="bibr">64</xref>). While the TR&#x3B1;1 trigger directly promotes transcription of CTNNB1 (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>), the effect generated by the TR&#x3B1;2 stimulation in SC compartment is still unknown. Cross-talk between THs-TR&#x3B1;1 and Wnt pathway has been confirmed by the up-regulation of several SC markers (<xref rid="B67" ref-type="bibr">67</xref>). Furthermore, it was reported that aberrant nuclear localization of &#x3B2;-catenin-induced by CTNNB1 mutations contributes to the progression of ATCs (<xref rid="B68" ref-type="bibr">68</xref>). Data reported by Todaro et al. showed that E-cadherin down-regulation together with &#x3B2;-catenin activation confers an invasive capacity and higher metastatic rate to thyroid CSCs (<xref rid="B18" ref-type="bibr">18</xref>).</p>
    </sec>
    <sec id="S4">
      <title>Growth Factors</title>
      <p>In thyroid, GFs exert their proliferative effects by inducing the RTK dimerization that activates the downstream PI3K pathway and the MAPK cascade via G-proteins (Figure <xref ref-type="fig" rid="F2">2</xref>). Alterations in genes involved in the MAPK pathway led to its constitutive activation, which represents a typical feature of TC (<xref rid="B1" ref-type="bibr">1</xref>). In particular, mutations in RET and NTRK and alterations in RAS and BRAF intracellular signal-transducers are clearly implicated in PTC pathogenesis (<xref rid="B69" ref-type="bibr">69</xref>). RAS point mutations and PAX8/PPAR&#x3B3; rearrangement have been frequently implicated in FTC pathogenesis (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>). The inactivation of <italic>RASAL1</italic> (encoding a RAS GTPase-activating protein) by hypermethylation and mutations provides a new genetic background for FTCs and ATCs (<xref rid="B72" ref-type="bibr">72</xref>). Besides nuclear &#x3B2;-catenin accumulation and p53 inactivation, oncogenic activation of MAPK and PI3K/Akt/Foxo3a are frequently found in ATCs (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>). The acquisition of a TERT promoter mutation was recently associated with clinical&#x2013;pathological aggressiveness in FTCs and BRAF mutation-positive PTCs (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B75" ref-type="bibr">75</xref>).</p>
      <p>The mesenchymal tissue is involved in thyroid development being that it releases Pro-epidermal growth factor (EGF) and basic fibroblast growth factor-2 (FGF-2), promoting cell proliferation and repressing differentiation (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). Estrogens play a pivotal role in this context by inducing the production of EGF and other TFs, such as TGF-&#x3B1; (<xref rid="B5" ref-type="bibr">5</xref>).</p>
      <p>After EGF binding, RTKs of the ErbB family (EGFR/ErbB1, ErbB2, ErbB3, and ErbB4) achieve activation through the arrangement in homo- and/or heterodimeric complexes (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>). In thyroid, TSH increases the expression of EGFRs that in turn promote the EGF mitogenic effect and contribute to gland homeostasis. The combination of specific EGFRs regulates the stimulation intensity, inducing transformation. Indeed, an increased expression of EGFRs in TCs compared to normal tissue has been reported (<xref rid="B80" ref-type="bibr">80</xref>). EGFR/ErbB1 over-expression and its constitutive phosphorylation have been observed on ATC samples and cell lines (<xref rid="B81" ref-type="bibr">81</xref>). Their expression has been retrieved in 90% of the PTC samples examined by Song (<xref rid="B82" ref-type="bibr">82</xref>). In combination with the repression of VEGF, EGF inhibitors could be a promising therapy for ATCs as demonstrated by <italic>in vitro</italic> studies (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). EGF is also supplemented in the serum-free culture medium, which is used to isolate SCs and CSCs <italic>in vitro</italic> (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B85" ref-type="bibr">85</xref>&#x2013;<xref rid="B90" ref-type="bibr">90</xref>).</p>
      <p>Similarly, the cell response to FGF is regulated by FGF RTKs (FGFRs 1&#x2013;4). FGF-2 exerts autocrine and paracrine stimulatory effects on thyroid growth, since the basement membrane of thyrocytes is able to produce FGF itself. FGF is also used <italic>in vitro</italic> for the maintenance of SC niche (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B91" ref-type="bibr">91</xref>); in particular, it could have an inhibitory effect on thyroid function through cAMP inhibition and TSH&#x2019;s activity weakening (<xref rid="B79" ref-type="bibr">79</xref>). In TC, increased FGF-2 levels and FGFR2 over-expression are critical in tumor progression and neovascularization (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>). Therefore, the differential expression in normal and malignant conditions could make this receptor a potential diagnostic marker for TCs (<xref rid="B94" ref-type="bibr">94</xref>).</p>
      <p>Growth factors also affect development and metabolic processes through insulin-like growth factor (IGF). After binding of their ligands, IGF receptors (IGF-Rs) autophosphorylate their intracellular domain and activate the MAPK and PI3K cascade (<xref rid="B95" ref-type="bibr">95</xref>). Consistently, IGF enhances the TSH mitogenic effect on follicular cells (<xref rid="B96" ref-type="bibr">96</xref>); on the other hand, it also cooperates with FGF-2 in establishing and maintaining the SC niche <italic>in vitro</italic> (<xref rid="B96" ref-type="bibr">96</xref>). Indeed, IGF pathway effectors are over-expressed in CSCs: IGFR2 is involved in an autocrine loop that sustains SC renewal, and IGF increases the expression of Oct-4 and Nanog when added to the culture medium (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>).</p>
    </sec>
    <sec id="S5">
      <title>Estrogen-Growth Factors Interacting Proteins</title>
      <p>Recently, there has been a focus on importance of the ER-GFs interacting proteins on cancer cell proliferation and invasivity. An example is mediator of ERbB2-driven cell motility (MEMO), which enhances ER-&#x3B1; extra-nuclear functions through the interaction with IGFR1 and ERbB2, activating MAPK and PI3K signaling (<xref rid="B99" ref-type="bibr">99</xref>).</p>
    </sec>
    <sec id="S6">
      <title>Concluding Remarks</title>
      <p>Since the theory of fetal carcinogenesis has initially been postulated, thyroid CSCs have been studied for their potential role as TICs. It has been hypothesized that various factors could be involved in the malignant transformation, such as aberrant molecular events converging to RTK, MAPK, and PI3K pathway activation. Besides the oncogenes contribution, it is likely that a network of various hormones and GFs could maintain the SC niche and enhance the proliferation of progenitors sustaining tumor bulk growth. Indeed, recent studies demonstrate that sexual hormones could exert a supportive role in the propagation of SCs and progenitors, as suggested by the cross-talk between estrogen-signaling and Wnt pathway. Furthermore, the latter pathway has also been observed interacting with THs in SC compartment and so accelerating tumorigenic processes. This mechanism could be benefited by the interaction between different cascades, which enhances or contrasts specific cellular response in tumor conditions. In conclusion, an in-depth study on the concert between estrogens, THs, and GFs could be helpful to elucidate hormones-driven thyroid carcinogenesis. Gaining more insight into this interaction could also explain the gender imbalance in tumor incidence for the purpose of identifying a more targeted approach in TC therapy.</p>
    </sec>
    <sec id="S7">
      <title>Conflict of Interest Statement</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>This study was supported by grants from AIRC to Giorgio Stassi (IG12819). Mariangela Zane is Ph.D., student in Oncology and Surgical Oncology at University of Padua. Emanuela Scavo and Marco Bonanno are Ph.D., students at University of Palermo, in International Immunopharmacology and in Cellular and Developmental Biology, respectively. We would like to thank Tatiana Terranova for her thoroughness and passion in editing this review.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Ezzat</surname><given-names>S</given-names></name><name><surname>Asa</surname><given-names>SL</given-names></name></person-group>
<article-title>Pathogenetic mechanisms in thyroid follicular-cell neoplasia</article-title>. <source>Nat Rev Cancer</source> (<year>2006</year>) <volume>6</volume>:<fpage>292</fpage>&#x2013;<lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nrc1836</pub-id><pub-id pub-id-type="pmid">16557281</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikiforova</surname><given-names>MN</given-names></name><name><surname>Nikiforov</surname><given-names>YE</given-names></name></person-group>
<article-title>Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis</article-title>. <source>Expert Rev Mol Diagn</source> (<year>2008</year>) <volume>8</volume>:<fpage>83</fpage>&#x2013;<lpage>95</lpage><pub-id pub-id-type="doi">10.1586/14737159.8.1.83</pub-id><pub-id pub-id-type="pmid">18088233</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smallridge</surname><given-names>RC</given-names></name><name><surname>Marlow</surname><given-names>LA</given-names></name><name><surname>Copland</surname><given-names>JA</given-names></name></person-group>
<article-title>Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies</article-title>. <source>Endocr Relat Cancer</source> (<year>2009</year>) <volume>16</volume>:<fpage>17</fpage>&#x2013;<lpage>44</lpage><pub-id pub-id-type="doi">10.1677/ERC-08-0154</pub-id><pub-id pub-id-type="pmid">18987168</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbari</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kebebew</surname><given-names>E</given-names></name></person-group>
<article-title>Thyroid cancer gender disparity</article-title>. <source>Future Oncol</source> (<year>2010</year>) <volume>6</volume>:<fpage>1771</fpage>&#x2013;<lpage>9</lpage><pub-id pub-id-type="doi">10.2217/fon.10.127</pub-id><pub-id pub-id-type="pmid">21142662</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajoria</surname><given-names>S</given-names></name><name><surname>Suriano</surname><given-names>R</given-names></name><name><surname>George</surname><given-names>AL</given-names></name><name><surname>Shanmugam</surname><given-names>A</given-names></name><name><surname>Jussim</surname><given-names>C</given-names></name><name><surname>Shin</surname><given-names>EJ</given-names></name><etal/></person-group>
<article-title>Estrogen activity as a preventive and therapeutic target in thyroid cancer</article-title>. <source>Biomed Pharmacother</source> (<year>2012</year>) <volume>66</volume>:<fpage>151</fpage>&#x2013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2011.11.010</pub-id><pub-id pub-id-type="pmid">22285105</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Naishadham</surname><given-names>D</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group>
<article-title>Cancer statistics, 2013</article-title>. <source>CA Cancer J Clin</source> (<year>2013</year>) <volume>63</volume>:<fpage>11</fpage>&#x2013;<lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21166</pub-id><pub-id pub-id-type="pmid">23335087</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajoria</surname><given-names>S</given-names></name><name><surname>Suriano</surname><given-names>R</given-names></name><name><surname>Shanmugam</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>YL</given-names></name><name><surname>Schantz</surname><given-names>SP</given-names></name><name><surname>Geliebter</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Metastatic phenotype is regulated by estrogen in thyroid cells</article-title>. <source>Thyroid</source> (<year>2010</year>) <volume>20</volume>:<fpage>33</fpage>&#x2013;<lpage>41</lpage><pub-id pub-id-type="doi">10.1089/thy.2009.0296</pub-id><pub-id pub-id-type="pmid">20067378</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Renko</surname><given-names>K</given-names></name><name><surname>Derwahl</surname><given-names>M</given-names></name></person-group>
<article-title>Oestrogen action on thyroid progenitor cells: relevant for the pathogenesis of thyroid nodules?</article-title>
<source>J Endocrinol</source> (<year>2013</year>) <volume>218</volume>:<fpage>125</fpage>&#x2013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1530/JOE-13-0029</pub-id><pub-id pub-id-type="pmid">23645248</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antico-Arciuch</surname><given-names>VG</given-names></name><name><surname>Dima</surname><given-names>M</given-names></name><name><surname>Liao</surname><given-names>XH</given-names></name><name><surname>Refetoff</surname><given-names>S</given-names></name><name><surname>Di Cristofano</surname><given-names>A</given-names></name></person-group>
<article-title>Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females</article-title>. <source>Oncogene</source> (<year>2010</year>) <volume>29</volume>:<fpage>5678</fpage>&#x2013;<lpage>86</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.308</pub-id><pub-id pub-id-type="pmid">20676139</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>GG</given-names></name><name><surname>Vlantis</surname><given-names>AC</given-names></name><name><surname>Van Hasselt</surname><given-names>CA</given-names></name></person-group>
<article-title>Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway</article-title>. <source>Cell Prolif</source> (<year>2007</year>) <volume>40</volume>:<fpage>921</fpage>&#x2013;<lpage>35</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2184.2007.00471.x</pub-id><pub-id pub-id-type="pmid">18021179</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceresini</surname><given-names>G</given-names></name><name><surname>Milli</surname><given-names>B</given-names></name><name><surname>Morganti</surname><given-names>S</given-names></name><name><surname>Maggio</surname><given-names>M</given-names></name><name><surname>Bacchi-Modena</surname><given-names>A</given-names></name><name><surname>Sgarabotto</surname><given-names>MP</given-names></name><etal/></person-group>
<article-title>Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women</article-title>. <source>Menopause</source> (<year>2008</year>) <volume>15</volume>:<fpage>326</fpage>&#x2013;<lpage>31</lpage><pub-id pub-id-type="doi">10.1097/gme.0b013e318148b83e</pub-id><pub-id pub-id-type="pmid">17998883</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaiman</surname><given-names>M</given-names></name><name><surname>Olevson</surname><given-names>Y</given-names></name><name><surname>Sandbank</surname><given-names>J</given-names></name><name><surname>Habler</surname><given-names>L</given-names></name><name><surname>Zehavi</surname><given-names>S</given-names></name><name><surname>Kessler</surname><given-names>A</given-names></name></person-group>
<article-title>Are estrogen receptors alpha detectable in normal and abnormal thyroid tissue?</article-title>
<source>Eur Arch Otorhinolaryngol</source> (<year>2010</year>) <volume>267</volume>:<fpage>1753</fpage>&#x2013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00405-010-1269-0</pub-id><pub-id pub-id-type="pmid">20473764</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Amino</surname><given-names>N</given-names></name></person-group>
<article-title>Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma</article-title>. <source>Thyroid</source> (<year>2005</year>) <volume>15</volume>:<fpage>432</fpage>&#x2013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1089/thy.2005.15.432</pub-id><pub-id pub-id-type="pmid">15929664</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>T</given-names></name></person-group>
<article-title>Fetal cell carcinogenesis of the thyroid: theory and practice</article-title>. <source>Semin Cancer Biol</source> (<year>2007</year>) <volume>17</volume>:<fpage>233</fpage>&#x2013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2006.02.001</pub-id><pub-id pub-id-type="pmid">16569505</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>L</given-names></name><name><surname>Sprick</surname><given-names>MR</given-names></name><name><surname>Kemper</surname><given-names>K</given-names></name><name><surname>Stassi</surname><given-names>G</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name></person-group>
<article-title>Cancer stem cells &#x2013; old concepts, new insights</article-title>. <source>Cell Death Differ</source> (<year>2008</year>) <volume>15</volume>:<fpage>947</fpage>&#x2013;<lpage>58</lpage><pub-id pub-id-type="doi">10.1038/cdd.2008.20</pub-id><pub-id pub-id-type="pmid">18259194</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>RY</given-names></name></person-group>
<article-title>Thyroid cancer stem cells</article-title>. <source>Nat Rev Endocrinol</source> (<year>2011</year>) <volume>7</volume>:<fpage>609</fpage>&#x2013;<lpage>16</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.127</pub-id><pub-id pub-id-type="pmid">21788969</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visvader</surname><given-names>JE</given-names></name></person-group>
<article-title>Cells of origin in cancer</article-title>. <source>Nature</source> (<year>2011</year>) <volume>469</volume>:<fpage>314</fpage>&#x2013;<lpage>22</lpage><pub-id pub-id-type="doi">10.1038/nature09781</pub-id><pub-id pub-id-type="pmid">21248838</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Iovino</surname><given-names>F</given-names></name><name><surname>Eterno</surname><given-names>V</given-names></name><name><surname>Cammareri</surname><given-names>P</given-names></name><name><surname>Gambara</surname><given-names>G</given-names></name><name><surname>Espina</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Tumorigenic and metastatic activity of human thyroid cancer stem cells</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>:<fpage>8874</fpage>&#x2013;<lpage>85</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1994</pub-id><pub-id pub-id-type="pmid">20959469</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastre-Perona</surname><given-names>A</given-names></name><name><surname>Santisteban</surname><given-names>P</given-names></name></person-group>
<article-title>Role of the wnt pathway in thyroid cancer</article-title>. <source>Front Endocrinol (Lausanne)</source> (<year>2012</year>) <volume>3</volume>:<fpage>31</fpage><pub-id pub-id-type="doi">10.3389/fendo.2012.00031</pub-id><pub-id pub-id-type="pmid">22645520</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Camp</surname><given-names>JK</given-names></name><name><surname>Beckers</surname><given-names>S</given-names></name><name><surname>Zegers</surname><given-names>D</given-names></name><name><surname>Van Hul</surname><given-names>W</given-names></name></person-group>
<article-title>Wnt signaling and the control of human stem cell fate</article-title>. <source>Stem Cell Rev</source> (<year>2014</year>) <volume>10</volume>:<fpage>207</fpage>&#x2013;<lpage>29</lpage><pub-id pub-id-type="doi">10.1007/s12015-013-9486-8</pub-id><pub-id pub-id-type="pmid">24323281</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakada</surname><given-names>D</given-names></name><name><surname>Oguro</surname><given-names>H</given-names></name><name><surname>Levi</surname><given-names>BP</given-names></name><name><surname>Ryan</surname><given-names>N</given-names></name><name><surname>Kitano</surname><given-names>A</given-names></name><name><surname>Saitoh</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy</article-title>. <source>Nature</source> (<year>2014</year>) <volume>505</volume>:<fpage>555</fpage>&#x2013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature12932</pub-id><pub-id pub-id-type="pmid">24451543</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manole</surname><given-names>D</given-names></name><name><surname>Schildknecht</surname><given-names>B</given-names></name><name><surname>Gosnell</surname><given-names>B</given-names></name><name><surname>Adams</surname><given-names>E</given-names></name><name><surname>Derwahl</surname><given-names>M</given-names></name></person-group>
<article-title>Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2001</year>) <volume>86</volume>:<fpage>1072</fpage>&#x2013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1210/jcem.86.3.7283</pub-id><pub-id pub-id-type="pmid">11238488</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>ML</given-names></name><name><surname>Chen</surname><given-names>GG</given-names></name><name><surname>Vlantis</surname><given-names>AC</given-names></name><name><surname>Tse</surname><given-names>GM</given-names></name><name><surname>Leung</surname><given-names>BC</given-names></name><name><surname>Van Hasselt</surname><given-names>CA</given-names></name></person-group>
<article-title>Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL</article-title>. <source>Cancer J</source> (<year>2005</year>) <volume>11</volume>:<fpage>113</fpage>&#x2013;<lpage>21</lpage><pub-id pub-id-type="doi">10.1097/00130404-200503000-00006</pub-id><pub-id pub-id-type="pmid">15969986</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Estrogen induces metastatic potential of papillary thyroid cancer cells through estrogen receptor alpha and beta</article-title>. <source>Int J Endocrinol</source> (<year>2013</year>) <volume>2013</volume>:<fpage>941568</fpage><pub-id pub-id-type="doi">10.1155/2013/941568</pub-id><pub-id pub-id-type="pmid">24222765</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santin</surname><given-names>AP</given-names></name><name><surname>Furlanetto</surname><given-names>TW</given-names></name></person-group>
<article-title>Role of estrogen in thyroid function and growth regulation</article-title>. <source>J Thyroid Res</source> (<year>2011</year>) <volume>2011</volume>:<fpage>875125</fpage><pub-id pub-id-type="doi">10.4061/2011/875125</pub-id><pub-id pub-id-type="pmid">21687614</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Arciuch Antico</surname><given-names>VG</given-names></name><name><surname>Di Cristofano</surname><given-names>A</given-names></name></person-group>
<article-title>Estrogen signaling and thyrocyte proliferation</article-title>. In: <person-group person-group-type="editor"><name><surname>Ward</surname><given-names>DL</given-names></name></person-group>, editor. <source>Thyroid and Parathyroid Diseases &#x2013; New Insights into Some Old and Some New Issues</source>. <publisher-name>InTech</publisher-name> (<year>2012</year>). <fpage>318</fpage> p.<pub-id pub-id-type="doi">10.5772/35913</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiruvengadam</surname><given-names>A</given-names></name><name><surname>Govindarajulu</surname><given-names>P</given-names></name><name><surname>Aruldhas</surname><given-names>MM</given-names></name></person-group>
<article-title>Modulatory effect of estradiol and testosterone on the development of N-nitrosodiisopropanolamine induced thyroid tumors in female rats</article-title>. <source>Endocr Res</source> (<year>2003</year>) <volume>29</volume>:<fpage>43</fpage>&#x2013;<lpage>51</lpage><pub-id pub-id-type="doi">10.1081/ERC-120018675</pub-id><pub-id pub-id-type="pmid">12665317</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heldring</surname><given-names>N</given-names></name><name><surname>Pike</surname><given-names>A</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Matthews</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Hartman</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Estrogen receptors: how do they signal and what are their targets</article-title>. <source>Physiol Rev</source> (<year>2007</year>) <volume>87</volume>:<fpage>905</fpage>&#x2013;<lpage>31</lpage><pub-id pub-id-type="doi">10.1152/physrev.00026.2006</pub-id><pub-id pub-id-type="pmid">17615392</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahid</surname><given-names>M</given-names></name><name><surname>Goldner</surname><given-names>W</given-names></name><name><surname>Beseler</surname><given-names>CL</given-names></name><name><surname>Rogan</surname><given-names>EG</given-names></name><name><surname>Cavalieri</surname><given-names>EL</given-names></name></person-group>
<article-title>Unbalanced estrogen metabolism in thyroid cancer</article-title>. <source>Int J Cancer</source> (<year>2013</year>) <volume>133</volume>:<fpage>2642</fpage>&#x2013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1002/ijc.28275</pub-id><pub-id pub-id-type="pmid">23686454</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Shan</surname><given-names>Z</given-names></name><name><surname>Teng</surname><given-names>W</given-names></name></person-group>
<article-title>Differential expression patterns and clinical significance of estrogen receptor-alpha and beta in papillary thyroid carcinoma</article-title>. <source>BMC Cancer</source> (<year>2014</year>) <volume>14</volume>:<fpage>383</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-14-383</pub-id><pub-id pub-id-type="pmid">24884830</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>R</given-names></name><name><surname>Van Hasselt</surname><given-names>A</given-names></name><name><surname>Vlantis</surname><given-names>AC</given-names></name><name><surname>Ng</surname><given-names>EK</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><name><surname>Fan</surname><given-names>MD</given-names></name><etal/></person-group>
<article-title>The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer</article-title>. <source>Cancer</source> (<year>2014</year>) <volume>120</volume>:<fpage>142</fpage>&#x2013;<lpage>53</lpage><pub-id pub-id-type="doi">10.1002/cncr.28383</pub-id><pub-id pub-id-type="pmid">24114184</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitman</surname><given-names>DC</given-names></name><name><surname>Paruthiyil</surname><given-names>S</given-names></name><name><surname>Vivar</surname><given-names>OI</given-names></name><name><surname>Saunier</surname><given-names>EF</given-names></name><name><surname>Herber</surname><given-names>CB</given-names></name><name><surname>Cohen</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Regulation of specific target genes and biological responses by estrogen receptor subtype agonists</article-title>. <source>Curr Opin Pharmacol</source> (<year>2010</year>) <volume>10</volume>:<fpage>629</fpage>&#x2013;<lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2010.09.009</pub-id><pub-id pub-id-type="pmid">20951642</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klinge</surname><given-names>CM</given-names></name></person-group>
<article-title>Estrogen receptor interaction with co-activators and co-repressors</article-title>. <source>Steroids</source> (<year>2000</year>) <volume>65</volume>:<fpage>227</fpage>&#x2013;<lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0039-128X(99)00107-5</pub-id><pub-id pub-id-type="pmid">10751636</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Makela</surname><given-names>S</given-names></name><name><surname>Treuter</surname><given-names>E</given-names></name><name><surname>Tujague</surname><given-names>M</given-names></name><name><surname>Thomsen</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Mechanisms of estrogen action</article-title>. <source>Physiol Rev</source> (<year>2001</year>) <volume>81</volume>:<fpage>1535</fpage>&#x2013;<lpage>65</lpage><pub-id pub-id-type="pmid">11581496</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornstrom</surname><given-names>L</given-names></name><name><surname>Sjoberg</surname><given-names>M</given-names></name></person-group>
<article-title>Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes</article-title>. <source>Mol Endocrinol</source> (<year>2005</year>) <volume>19</volume>:<fpage>833</fpage>&#x2013;<lpage>42</lpage><pub-id pub-id-type="doi">10.1210/me.2004-0486</pub-id><pub-id pub-id-type="pmid">15695368</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascenzi</surname><given-names>P</given-names></name><name><surname>Bocedi</surname><given-names>A</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name></person-group>
<article-title>Structure-function relationship of estrogen receptor alpha and beta: impact on human health</article-title>. <source>Mol Aspects Med</source> (<year>2006</year>) <volume>27</volume>:<fpage>299</fpage>&#x2013;<lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2006.07.001</pub-id><pub-id pub-id-type="pmid">16914190</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osmanbeyoglu</surname><given-names>HU</given-names></name><name><surname>Lu</surname><given-names>KN</given-names></name><name><surname>Oesterreich</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>RS</given-names></name><name><surname>Benos</surname><given-names>PV</given-names></name><name><surname>Coronnello</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Estrogen represses gene expression through reconfiguring chromatin structures</article-title>. <source>Nucleic Acids Res</source> (<year>2013</year>) <volume>41</volume>:<fpage>8061</fpage>&#x2013;<lpage>71</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt586</pub-id><pub-id pub-id-type="pmid">23821662</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acconcia</surname><given-names>F</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name></person-group>
<article-title>Signaling regulation of genomic and nongenomic functions of estrogen receptors</article-title>. <source>Cancer Lett</source> (<year>2006</year>) <volume>238</volume>:<fpage>1</fpage>&#x2013;<lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.06.018</pub-id><pub-id pub-id-type="pmid">16084012</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JQ</given-names></name><name><surname>Brown</surname><given-names>TR</given-names></name><name><surname>Yager</surname><given-names>JD</given-names></name></person-group>
<article-title>Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria</article-title>. <source>Adv Exp Med Biol</source> (<year>2008</year>) <volume>630</volume>:<fpage>1</fpage>&#x2013;<lpage>18</lpage><pub-id pub-id-type="doi">10.1007/978-0-387-78818-0_1</pub-id><pub-id pub-id-type="pmid">18637481</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>YY</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>YX</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name><name><surname>Wan</surname><given-names>XP</given-names></name></person-group>
<article-title>Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway</article-title>. <source>Cancer Sci</source> (<year>2009</year>) <volume>100</volume>:<fpage>1051</fpage>&#x2013;<lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01148.x</pub-id><pub-id pub-id-type="pmid">19432902</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman-Blas</surname><given-names>JA</given-names></name><name><surname>Castaneda</surname><given-names>S</given-names></name><name><surname>Largo</surname><given-names>R</given-names></name><name><surname>Herrero-Beaumont</surname><given-names>G</given-names></name></person-group>
<article-title>Osteoarthritis associated with estrogen deficiency</article-title>. <source>Arthritis Res Ther</source> (<year>2009</year>) <volume>11</volume>:<fpage>241</fpage><pub-id pub-id-type="doi">10.1186/ar2791</pub-id><pub-id pub-id-type="pmid">19804619</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>LP</given-names></name><name><surname>Barros</surname><given-names>IA</given-names></name><name><surname>Lisboa</surname><given-names>PC</given-names></name><name><surname>Araujo</surname><given-names>RL</given-names></name><name><surname>Silva</surname><given-names>AC</given-names></name><name><surname>Rosenthal</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats</article-title>. <source>Steroids</source> (<year>2006</year>) <volume>71</volume>:<fpage>653</fpage>&#x2013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2006.03.007</pub-id><pub-id pub-id-type="pmid">16762383</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlanetto</surname><given-names>TW</given-names></name><name><surname>Nguyen</surname><given-names>LQ</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group>
<article-title>Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells</article-title>. <source>Endocrinology</source> (<year>1999</year>) <volume>140</volume>:<fpage>5705</fpage>&#x2013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1210/endo.140.12.7197</pub-id><pub-id pub-id-type="pmid">10579335</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajoria</surname><given-names>S</given-names></name><name><surname>Suriano</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>YL</given-names></name><name><surname>George</surname><given-names>AL</given-names></name><name><surname>Geliebter</surname><given-names>J</given-names></name><name><surname>Schantz</surname><given-names>SP</given-names></name><etal/></person-group>
<article-title>Estradiol-mediated tumor neo-vascularization</article-title>. <source>Oncol Lett</source> (<year>2011</year>) <volume>2</volume>:<fpage>453</fpage>&#x2013;<lpage>7</lpage><pub-id pub-id-type="doi">10.3892/ol.2011.283</pub-id><pub-id pub-id-type="pmid">22866102</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouzmenko</surname><given-names>AP</given-names></name><name><surname>Takeyama</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Furutani</surname><given-names>T</given-names></name><name><surname>Sawatsubashi</surname><given-names>S</given-names></name><name><surname>Maki</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Wnt/beta-catenin and estrogen signaling converge in vivo</article-title>. <source>J Biol Chem</source> (<year>2004</year>) <volume>279</volume>:<fpage>40255</fpage>&#x2013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1074/jbc.C400331200</pub-id><pub-id pub-id-type="pmid">15304487</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postiglione</surname><given-names>MP</given-names></name><name><surname>Parlato</surname><given-names>R</given-names></name><name><surname>Rodriguez-Mallon</surname><given-names>A</given-names></name><name><surname>Rosica</surname><given-names>A</given-names></name><name><surname>Mithbaokar</surname><given-names>P</given-names></name><name><surname>Maresca</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2002</year>) <volume>99</volume>:<fpage>15462</fpage>&#x2013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.242328999</pub-id><pub-id pub-id-type="pmid">12432093</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>DL</given-names></name><name><surname>Santisteban</surname><given-names>P</given-names></name></person-group>
<article-title>Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems</article-title>. <source>Eur J Endocrinol</source> (<year>2000</year>) <volume>143</volume>:<fpage>161</fpage>&#x2013;<lpage>78</lpage><pub-id pub-id-type="doi">10.1530/eje.0.1430161</pub-id><pub-id pub-id-type="pmid">10913934</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Van Keymeulen</surname><given-names>A</given-names></name><name><surname>Golstein</surname><given-names>J</given-names></name><name><surname>Fusco</surname><given-names>A</given-names></name><name><surname>Dumont</surname><given-names>JE</given-names></name><name><surname>Roger</surname><given-names>PP</given-names></name></person-group>
<article-title>Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models</article-title>. <source>Endocr Rev</source> (<year>2001</year>) <volume>22</volume>:<fpage>631</fpage>&#x2013;<lpage>56</lpage><pub-id pub-id-type="doi">10.1210/edrv.22.5.0444</pub-id><pub-id pub-id-type="pmid">11588145</pub-id></mixed-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cass</surname><given-names>LA</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name><name><surname>Prendergast</surname><given-names>GV</given-names></name><name><surname>Backer</surname><given-names>JM</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name><name><surname>Meinkoth</surname><given-names>JL</given-names></name></person-group>
<article-title>Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation</article-title>. <source>Mol Cell Biol</source> (<year>1999</year>) <volume>19</volume>:<fpage>5882</fpage>&#x2013;<lpage>91</lpage><pub-id pub-id-type="pmid">10454535</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roger</surname><given-names>PP</given-names></name><name><surname>Van Staveren</surname><given-names>WC</given-names></name><name><surname>Coulonval</surname><given-names>K</given-names></name><name><surname>Dumont</surname><given-names>JE</given-names></name><name><surname>Maenhaut</surname><given-names>C</given-names></name></person-group>
<article-title>Signal transduction in the human thyrocyte and its perversion in thyroid tumors</article-title>. <source>Mol Cell Endocrinol</source> (<year>2010</year>) <volume>321</volume>:<fpage>3</fpage>&#x2013;<lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2009.11.015</pub-id><pub-id pub-id-type="pmid">19962425</pub-id></mixed-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kursawe</surname><given-names>R</given-names></name><name><surname>Paschke</surname><given-names>R</given-names></name></person-group>
<article-title>Modulation of TSHR signaling by posttranslational modifications</article-title>. <source>Trends Endocrinol Metab</source> (<year>2007</year>) <volume>18</volume>:<fpage>199</fpage>&#x2013;<lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2007.05.002</pub-id><pub-id pub-id-type="pmid">17524661</pub-id></mixed-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallini</surname><given-names>G</given-names></name></person-group>
<article-title>Molecular pathobiology of thyroid neoplasms</article-title>. <source>Endocr Pathol</source> (<year>2002</year>) <volume>13</volume>:<fpage>271</fpage>&#x2013;<lpage>88</lpage><pub-id pub-id-type="doi">10.1385/EP:13:4:271</pub-id><pub-id pub-id-type="pmid">12665646</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krohn</surname><given-names>K</given-names></name><name><surname>Fuhrer</surname><given-names>D</given-names></name><name><surname>Bayer</surname><given-names>Y</given-names></name><name><surname>Eszlinger</surname><given-names>M</given-names></name><name><surname>Brauer</surname><given-names>V</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Molecular pathogenesis of euthyroid and toxic multinodular goiter</article-title>. <source>Endocr Rev</source> (<year>2005</year>) <volume>26</volume>:<fpage>504</fpage>&#x2013;<lpage>24</lpage><pub-id pub-id-type="doi">10.1210/er.2004-0005</pub-id><pub-id pub-id-type="pmid">15615818</pub-id></mixed-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name><name><surname>Gejman</surname><given-names>PV</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name></person-group>
<article-title>The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms</article-title>. <source>J Clin Endocrinol Metab</source> (<year>1993</year>) <volume>76</volume>:<fpage>1446</fpage>&#x2013;<lpage>51</lpage><pub-id pub-id-type="doi">10.1210/jcem.76.6.8501149</pub-id><pub-id pub-id-type="pmid">8501149</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spambalg</surname><given-names>D</given-names></name><name><surname>Sharifi</surname><given-names>N</given-names></name><name><surname>Elisei</surname><given-names>R</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Medeiros-Neto</surname><given-names>G</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name></person-group>
<article-title>Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation</article-title>. <source>J Clin Endocrinol Metab</source> (<year>1996</year>) <volume>81</volume>:<fpage>3898</fpage>&#x2013;<lpage>901</lpage><pub-id pub-id-type="doi">10.1210/jcem.81.11.8923835</pub-id><pub-id pub-id-type="pmid">8923835</pub-id></mixed-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group>
<article-title>Wnt signalling in stem cells and cancer</article-title>. <source>Nature</source> (<year>2005</year>) <volume>434</volume>:<fpage>843</fpage>&#x2013;<lpage>50</lpage><pub-id pub-id-type="doi">10.1038/nature03319</pub-id><pub-id pub-id-type="pmid">15829953</pub-id></mixed-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WB</given-names></name><name><surname>Lewis</surname><given-names>CJ</given-names></name><name><surname>Mccall</surname><given-names>KD</given-names></name><name><surname>Malgor</surname><given-names>R</given-names></name><name><surname>Kohn</surname><given-names>AD</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><etal/></person-group>
<article-title>Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms</article-title>. <source>J Endocrinol</source> (<year>2007</year>) <volume>193</volume>:<fpage>93</fpage>&#x2013;<lpage>106</lpage><pub-id pub-id-type="doi">10.1677/JOE-06-0025</pub-id><pub-id pub-id-type="pmid">17400807</pub-id></mixed-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>You</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Mou</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Regulation of GSK-3 beta in the proliferation and apoptosis of human thyrocytes investigated using a GSK-3 beta-targeting RNAi adenovirus expression vector: involvement the Wnt/beta-catenin pathway</article-title>. <source>Mol Biol Rep</source> (<year>2010</year>) <volume>37</volume>:<fpage>2773</fpage>&#x2013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s11033-009-9819-5</pub-id><pub-id pub-id-type="pmid">19757160</pub-id></mixed-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>A</given-names></name><name><surname>Aranda</surname><given-names>A</given-names></name></person-group>
<article-title>Thyroid hormone receptors, cell growth and differentiation</article-title>. <source>Biochim Biophys Acta</source> (<year>2013</year>) <volume>1830</volume>:<fpage>3908</fpage>&#x2013;<lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2012.03.012</pub-id><pub-id pub-id-type="pmid">22484490</pub-id></mixed-citation>
      </ref>
      <ref id="B60">
        <label>60</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>SY</given-names></name><name><surname>Leonard</surname><given-names>JL</given-names></name><name><surname>Davis</surname><given-names>PJ</given-names></name></person-group>
<article-title>Molecular aspects of thyroid hormone actions</article-title>. <source>Endocr Rev</source> (<year>2010</year>) <volume>31</volume>:<fpage>139</fpage>&#x2013;<lpage>70</lpage><pub-id pub-id-type="doi">10.1210/er.2009-0007</pub-id><pub-id pub-id-type="pmid">20051527</pub-id></mixed-citation>
      </ref>
      <ref id="B61">
        <label>61</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>PM</given-names></name><name><surname>Ando</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Maruvada</surname><given-names>P</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name></person-group>
<article-title>Thyroid hormone action at the cellular, genomic and target gene levels</article-title>. <source>Mol Cell Endocrinol</source> (<year>2006</year>) <volume>246</volume>:<fpage>121</fpage>&#x2013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2005.11.030</pub-id><pub-id pub-id-type="pmid">16442701</pub-id></mixed-citation>
      </ref>
      <ref id="B62">
        <label>62</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>H</given-names></name><name><surname>Givel</surname><given-names>F</given-names></name><name><surname>Perroud</surname><given-names>M</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group>
<article-title>Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements</article-title>. <source>Mol Endocrinol</source> (<year>1995</year>) <volume>9</volume>:<fpage>794</fpage>&#x2013;<lpage>804</lpage><pub-id pub-id-type="doi">10.1210/mend.9.7.7476963</pub-id><pub-id pub-id-type="pmid">7476963</pub-id></mixed-citation>
      </ref>
      <ref id="B63">
        <label>63</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banu</surname><given-names>SK</given-names></name><name><surname>Govindarajulu</surname><given-names>P</given-names></name><name><surname>Aruldhas</surname><given-names>MM</given-names></name></person-group>
<article-title>Developmental profiles of TSH, sex steroids, and their receptors in the thyroid and their relevance to thyroid growth in immature rats</article-title>. <source>Steroids</source> (<year>2002</year>) <volume>67</volume>:<fpage>137</fpage>&#x2013;<lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0039-128X(01)00144-1</pub-id><pub-id pub-id-type="pmid">11755178</pub-id></mixed-citation>
      </ref>
      <ref id="B64">
        <label>64</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WG</given-names></name><name><surname>Cheng</surname><given-names>SY</given-names></name></person-group>
<article-title>Thyroid hormone receptors and cancer</article-title>. <source>Biochim Biophys Acta</source> (<year>2013</year>) <volume>1830</volume>:<fpage>3928</fpage>&#x2013;<lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2012.04.002</pub-id><pub-id pub-id-type="pmid">22507269</pub-id></mixed-citation>
      </ref>
      <ref id="B65">
        <label>65</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plateroti</surname><given-names>M</given-names></name><name><surname>Kress</surname><given-names>E</given-names></name><name><surname>Mori</surname><given-names>JI</given-names></name><name><surname>Samarut</surname><given-names>J</given-names></name></person-group>
<article-title>Thyroid hormone receptor alpha1 directly controls transcription of the beta-catenin gene in intestinal epithelial cells</article-title>. <source>Mol Cell Biol</source> (<year>2006</year>) <volume>26</volume>:<fpage>3204</fpage>&#x2013;<lpage>14</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.8.3204-3214.2006</pub-id><pub-id pub-id-type="pmid">16581794</pub-id></mixed-citation>
      </ref>
      <ref id="B66">
        <label>66</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kress</surname><given-names>E</given-names></name><name><surname>Samarut</surname><given-names>J</given-names></name><name><surname>Plateroti</surname><given-names>M</given-names></name></person-group>
<article-title>Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality?</article-title>
<source>Mol Cell Endocrinol</source> (<year>2009</year>) <volume>313</volume>:<fpage>36</fpage>&#x2013;<lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2009.08.028</pub-id><pub-id pub-id-type="pmid">19737599</pub-id></mixed-citation>
      </ref>
      <ref id="B67">
        <label>67</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kress</surname><given-names>E</given-names></name><name><surname>Skah</surname><given-names>S</given-names></name><name><surname>Sirakov</surname><given-names>M</given-names></name><name><surname>Nadjar</surname><given-names>J</given-names></name><name><surname>Gadot</surname><given-names>N</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name><etal/></person-group>
<article-title>Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis</article-title>. <source>Gastroenterology</source> (<year>2010</year>) <volume>138</volume>:<fpage>1863</fpage>&#x2013;<lpage>74</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.01.041</pub-id><pub-id pub-id-type="pmid">20114049</pub-id></mixed-citation>
      </ref>
      <ref id="B68">
        <label>68</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Rostan</surname><given-names>G</given-names></name><name><surname>Camp</surname><given-names>RL</given-names></name><name><surname>Herrero</surname><given-names>A</given-names></name><name><surname>Carcangiu</surname><given-names>ML</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name><name><surname>Tallini</surname><given-names>G</given-names></name></person-group>
<article-title>Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis</article-title>. <source>Am J Pathol</source> (<year>2001</year>) <volume>158</volume>:<fpage>987</fpage>&#x2013;<lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64045-X</pub-id><pub-id pub-id-type="pmid">11238046</pub-id></mixed-citation>
      </ref>
      <ref id="B69">
        <label>69</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikiforov</surname><given-names>YE</given-names></name><name><surname>Nikiforova</surname><given-names>MN</given-names></name></person-group>
<article-title>Molecular genetics and diagnosis of thyroid cancer</article-title>. <source>Nat Rev Endocrinol</source> (<year>2011</year>) <volume>7</volume>:<fpage>569</fpage>&#x2013;<lpage>80</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.142</pub-id><pub-id pub-id-type="pmid">21878896</pub-id></mixed-citation>
      </ref>
      <ref id="B70">
        <label>70</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroll</surname><given-names>TG</given-names></name><name><surname>Sarraf</surname><given-names>P</given-names></name><name><surname>Pecciarini</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Mueller</surname><given-names>E</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><etal/></person-group>
<article-title>PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]</article-title>. <source>Science</source> (<year>2000</year>) <volume>289</volume>:<fpage>1357</fpage>&#x2013;<lpage>60</lpage><pub-id pub-id-type="doi">10.1126/science.289.5483.1357</pub-id><pub-id pub-id-type="pmid">10958784</pub-id></mixed-citation>
      </ref>
      <ref id="B71">
        <label>71</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Rostan</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Camp</surname><given-names>RL</given-names></name><name><surname>Pollan</surname><given-names>M</given-names></name><name><surname>Herrero</surname><given-names>A</given-names></name><name><surname>Pardo</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer</article-title>. <source>J Clin Oncol</source> (<year>2003</year>) <volume>21</volume>:<fpage>3226</fpage>&#x2013;<lpage>35</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.10.130</pub-id><pub-id pub-id-type="pmid">12947056</pub-id></mixed-citation>
      </ref>
      <ref id="B72">
        <label>72</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Bojdani</surname><given-names>E</given-names></name><name><surname>Murugan</surname><given-names>AK</given-names></name><name><surname>Xing</surname><given-names>M</given-names></name></person-group>
<article-title>Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer</article-title>. <source>J Natl Cancer Inst</source> (<year>2013</year>) <volume>105</volume>:<fpage>1617</fpage>&#x2013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1093/jnci/djt249</pub-id><pub-id pub-id-type="pmid">24136889</pub-id></mixed-citation>
      </ref>
      <ref id="B73">
        <label>73</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellelli</surname><given-names>R</given-names></name><name><surname>Castellone</surname><given-names>MD</given-names></name><name><surname>Garcia-Rostan</surname><given-names>G</given-names></name><name><surname>Ugolini</surname><given-names>C</given-names></name><name><surname>Nucera</surname><given-names>C</given-names></name><name><surname>Sadow</surname><given-names>PM</given-names></name><etal/></person-group>
<article-title>FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma</article-title>. <source>Endocr Relat Cancer</source> (<year>2012</year>) <volume>19</volume>:<fpage>695</fpage>&#x2013;<lpage>710</lpage><pub-id pub-id-type="doi">10.1530/ERC-12-0031</pub-id><pub-id pub-id-type="pmid">22919068</pub-id></mixed-citation>
      </ref>
      <ref id="B74">
        <label>74</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nehs</surname><given-names>MA</given-names></name><name><surname>Nucera</surname><given-names>C</given-names></name><name><surname>Nagarkatti</surname><given-names>SS</given-names></name><name><surname>Sadow</surname><given-names>PM</given-names></name><name><surname>Morales-Garcia</surname><given-names>D</given-names></name><name><surname>Hodin</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer</article-title>. <source>Endocrinology</source> (<year>2012</year>) <volume>153</volume>:<fpage>985</fpage>&#x2013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1210/en.2011-1519</pub-id><pub-id pub-id-type="pmid">22202162</pub-id></mixed-citation>
      </ref>
      <ref id="B75">
        <label>75</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landa</surname><given-names>I</given-names></name><name><surname>Ganly</surname><given-names>I</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Mitsutake</surname><given-names>N</given-names></name><name><surname>Matsuse</surname><given-names>M</given-names></name><name><surname>Ibrahimpasic</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2013</year>) <volume>98</volume>:<fpage>E1562</fpage>&#x2013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2383</pub-id><pub-id pub-id-type="pmid">23833040</pub-id></mixed-citation>
      </ref>
      <ref id="B76">
        <label>76</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>M</given-names></name><name><surname>Di Lauro</surname><given-names>R</given-names></name></person-group>
<article-title>Thyroid development and its disorders: genetics and molecular mechanisms</article-title>. <source>Endocr Rev</source> (<year>2004</year>) <volume>25</volume>:<fpage>722</fpage>&#x2013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1210/er.2003-0028</pub-id><pub-id pub-id-type="pmid">15466939</pub-id></mixed-citation>
      </ref>
      <ref id="B77">
        <label>77</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagman</surname><given-names>H</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name></person-group>
<article-title>Morphogenetics of early thyroid development</article-title>. <source>J Mol Endocrinol</source> (<year>2011</year>) <volume>46</volume>:<fpage>R33</fpage>&#x2013;<lpage>42</lpage><pub-id pub-id-type="doi">10.1677/JME-10-0084</pub-id><pub-id pub-id-type="pmid">21322126</pub-id></mixed-citation>
      </ref>
      <ref id="B78">
        <label>78</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarden</surname><given-names>Y</given-names></name><name><surname>Sliwkowski</surname><given-names>MX</given-names></name></person-group>
<article-title>Untangling the ErbB signalling network</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2001</year>) <volume>2</volume>:<fpage>127</fpage>&#x2013;<lpage>37</lpage><pub-id pub-id-type="doi">10.1038/35052073</pub-id><pub-id pub-id-type="pmid">11252954</pub-id></mixed-citation>
      </ref>
      <ref id="B79">
        <label>79</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Konturek</surname><given-names>A</given-names></name></person-group>
<article-title>Thyroid growth factors</article-title>. In: <person-group person-group-type="editor"><name><surname>Ward</surname><given-names>DL</given-names></name></person-group>, editor. <source>Thyroid and Parathyroid Diseases &#x2013; New Insight into Some Old and Some New Issues</source>. <publisher-name>InTech</publisher-name> (<year>2012</year>). <fpage>318</fpage> p.<pub-id pub-id-type="doi">10.5772/37570</pub-id></mixed-citation>
      </ref>
      <ref id="B80">
        <label>80</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Nishii</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>H</given-names></name><name><surname>Ishiguro</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Expression of erbB receptors mRNA in thyroid tissues</article-title>. <source>Biochim Biophys Acta</source> (<year>2004</year>) <volume>1673</volume>:<fpage>194</fpage>&#x2013;<lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2004.04.016</pub-id><pub-id pub-id-type="pmid">15279891</pub-id></mixed-citation>
      </ref>
      <ref id="B81">
        <label>81</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergstrom</surname><given-names>JD</given-names></name><name><surname>Westermark</surname><given-names>B</given-names></name><name><surname>Heldin</surname><given-names>NE</given-names></name></person-group>
<article-title>Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells</article-title>. <source>Exp Cell Res</source> (<year>2000</year>) <volume>259</volume>:<fpage>293</fpage>&#x2013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1006/excr.2000.4967</pub-id><pub-id pub-id-type="pmid">10942601</pub-id></mixed-citation>
      </ref>
      <ref id="B82">
        <label>82</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>B</given-names></name></person-group>
<article-title>Immunohistochemical demonstration of epidermal growth factor receptor and ceruloplasmin in thyroid diseases</article-title>. <source>Acta Pathol Jpn</source> (<year>1991</year>) <volume>41</volume>:<fpage>336</fpage>&#x2013;<lpage>43</lpage><pub-id pub-id-type="pmid">1867098</pub-id></mixed-citation>
      </ref>
      <ref id="B83">
        <label>83</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiff</surname><given-names>BA</given-names></name><name><surname>Mcmurphy</surname><given-names>AB</given-names></name><name><surname>Jasser</surname><given-names>SA</given-names></name><name><surname>Younes</surname><given-names>MN</given-names></name><name><surname>Doan</surname><given-names>D</given-names></name><name><surname>Yigitbasi</surname><given-names>OG</given-names></name><etal/></person-group>
<article-title>Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer</article-title>. <source>Clin Cancer Res</source> (<year>2004</year>) <volume>10</volume>:<fpage>8594</fpage>&#x2013;<lpage>602</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0690</pub-id><pub-id pub-id-type="pmid">15623643</pub-id></mixed-citation>
      </ref>
      <ref id="B84">
        <label>84</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Glaser</surname><given-names>S</given-names></name><name><surname>Wunderlich</surname><given-names>A</given-names></name><name><surname>Lingelbach</surname><given-names>S</given-names></name><name><surname>Dietrich</surname><given-names>C</given-names></name><name><surname>Burchert</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors &#x2013; a novel antiproliferative/antiangiogenic strategy in thyroid cancer</article-title>. <source>Langenbecks Arch Surg</source> (<year>2006</year>) <volume>391</volume>:<fpage>589</fpage>&#x2013;<lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s00423-006-0104-y</pub-id><pub-id pub-id-type="pmid">17053904</pub-id></mixed-citation>
      </ref>
      <ref id="B85">
        <label>85</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>L</given-names></name><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Nowka</surname><given-names>K</given-names></name><name><surname>Derwahl</surname><given-names>M</given-names></name></person-group>
<article-title>Stem cells derived from goiters in adults form spheres in response to intense growth stimulation and require thyrotropin for differentiation into thyrocytes</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2007</year>) <volume>92</volume>:<fpage>3681</fpage>&#x2013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1210/jc.2007-0281</pub-id><pub-id pub-id-type="pmid">17609303</pub-id></mixed-citation>
      </ref>
      <ref id="B86">
        <label>86</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Brabant</surname><given-names>G</given-names></name><name><surname>Derwahl</surname><given-names>M</given-names></name></person-group>
<article-title>Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells</article-title>. <source>Int J Oncol</source> (<year>2010</year>) <volume>37</volume>:<fpage>307</fpage>&#x2013;<lpage>15</lpage><pub-id pub-id-type="doi">10.3892/ijo_00000679</pub-id><pub-id pub-id-type="pmid">20596658</pub-id></mixed-citation>
      </ref>
      <ref id="B87">
        <label>87</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>R</given-names></name><name><surname>Frasca</surname><given-names>F</given-names></name><name><surname>Garozzo</surname><given-names>A</given-names></name><name><surname>Giani</surname><given-names>F</given-names></name><name><surname>Pandini</surname><given-names>G</given-names></name><name><surname>Vella</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2011</year>) <volume>96</volume>:<fpage>766</fpage>&#x2013;<lpage>74</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-1255</pub-id><pub-id pub-id-type="pmid">21123448</pub-id></mixed-citation>
      </ref>
      <ref id="B88">
        <label>88</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>LM</given-names></name><name><surname>Huang</surname><given-names>PI</given-names></name><name><surname>Chen</surname><given-names>YR</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Chou</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>YW</given-names></name><etal/></person-group>
<article-title>Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells</article-title>. <source>J Pharmacol Exp Ther</source> (<year>2012</year>) <volume>341</volume>:<fpage>410</fpage>&#x2013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1124/jpet.111.188730</pub-id><pub-id pub-id-type="pmid">22328572</pub-id></mixed-citation>
      </ref>
      <ref id="B89">
        <label>89</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Reeb</surname><given-names>AN</given-names></name><name><surname>Sewell</surname><given-names>WA</given-names></name><name><surname>Elhomsy</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>RY</given-names></name></person-group>
<article-title>Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e65095</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0065095</pub-id><pub-id pub-id-type="pmid">23724124</pub-id></mixed-citation>
      </ref>
      <ref id="B90">
        <label>90</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Henderson</surname><given-names>YC</given-names></name><name><surname>Williams</surname><given-names>MD</given-names></name><name><surname>Lai</surname><given-names>SY</given-names></name><name><surname>Clayman</surname><given-names>GL</given-names></name></person-group>
<article-title>Detection of thyroid cancer stem cells in papillary thyroid carcinoma</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2014</year>) <volume>99</volume>:<fpage>536</fpage>&#x2013;<lpage>44</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2558</pub-id><pub-id pub-id-type="pmid">24302752</pub-id></mixed-citation>
      </ref>
      <ref id="B91">
        <label>91</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longmire</surname><given-names>TA</given-names></name><name><surname>Ikonomou</surname><given-names>L</given-names></name><name><surname>Hawkins</surname><given-names>F</given-names></name><name><surname>Christodoulou</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Jean</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>Efficient derivation of purified lung and thyroid progenitors from embryonic stem cells</article-title>. <source>Cell Stem Cell</source> (<year>2012</year>) <volume>10</volume>:<fpage>398</fpage>&#x2013;<lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.01.019</pub-id><pub-id pub-id-type="pmid">22482505</pub-id></mixed-citation>
      </ref>
      <ref id="B92">
        <label>92</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggo</surname><given-names>MC</given-names></name><name><surname>Hopkins</surname><given-names>JM</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name><name><surname>Johnson</surname><given-names>GD</given-names></name><name><surname>Sanders</surname><given-names>DS</given-names></name><name><surname>Sheppard</surname><given-names>MC</given-names></name></person-group>
<article-title>Expression of fibroblast growth factors in thyroid cancer</article-title>. <source>J Clin Endocrinol Metab</source> (<year>1995</year>) <volume>80</volume>:<fpage>1006</fpage>&#x2013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1210/jcem.80.3.7533768</pub-id><pub-id pub-id-type="pmid">7533768</pub-id></mixed-citation>
      </ref>
      <ref id="B93">
        <label>93</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Serra</surname><given-names>S</given-names></name><name><surname>Asa</surname><given-names>SL</given-names></name><name><surname>Ezzat</surname><given-names>S</given-names></name></person-group>
<article-title>FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression</article-title>. <source>Cancer Res</source> (<year>2012</year>) <volume>72</volume>:<fpage>2017</fpage>&#x2013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3985</pub-id><pub-id pub-id-type="pmid">22345151</pub-id></mixed-citation>
      </ref>
      <ref id="B94">
        <label>94</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redler</surname><given-names>A</given-names></name><name><surname>Di Rocco</surname><given-names>G</given-names></name><name><surname>Giannotti</surname><given-names>D</given-names></name><name><surname>Frezzotti</surname><given-names>F</given-names></name><name><surname>Bernieri</surname><given-names>MG</given-names></name><name><surname>Ceccarelli</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Fibroblast growth factor receptor-2 expression in thyroid tumor progression: potential diagnostic application</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e72224</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0072224</pub-id><pub-id pub-id-type="pmid">23977259</pub-id></mixed-citation>
      </ref>
      <ref id="B95">
        <label>95</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laron</surname><given-names>Z</given-names></name></person-group>
<article-title>Insulin-like growth factor 1 (IGF-1): a growth hormone</article-title>. <source>Mol Pathol</source> (<year>2001</year>) <volume>54</volume>:<fpage>311</fpage>&#x2013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1136/mp.54.5.311</pub-id><pub-id pub-id-type="pmid">11577173</pub-id></mixed-citation>
      </ref>
      <ref id="B96">
        <label>96</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendall</surname><given-names>SC</given-names></name><name><surname>Stewart</surname><given-names>MH</given-names></name><name><surname>Menendez</surname><given-names>P</given-names></name><name><surname>George</surname><given-names>D</given-names></name><name><surname>Vijayaragavan</surname><given-names>K</given-names></name><name><surname>Werbowetski-Ogilvie</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro</article-title>. <source>Nature</source> (<year>2007</year>) <volume>448</volume>:<fpage>1015</fpage>&#x2013;<lpage>21</lpage><pub-id pub-id-type="doi">10.1038/nature06027</pub-id><pub-id pub-id-type="pmid">17625568</pub-id></mixed-citation>
      </ref>
      <ref id="B97">
        <label>97</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>V</given-names></name><name><surname>Pandini</surname><given-names>G</given-names></name><name><surname>Sciacca</surname><given-names>L</given-names></name><name><surname>Mineo</surname><given-names>R</given-names></name><name><surname>Vigneri</surname><given-names>R</given-names></name><name><surname>Pezzino</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2002</year>) <volume>87</volume>:<fpage>245</fpage>&#x2013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1210/jcem.87.1.8142</pub-id><pub-id pub-id-type="pmid">11788654</pub-id></mixed-citation>
      </ref>
      <ref id="B98">
        <label>98</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>R</given-names></name><name><surname>Belfiore</surname><given-names>A</given-names></name></person-group>
<article-title>The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells</article-title>. <source>Front Endocrinol (Lausanne)</source> (<year>2014</year>) <volume>5</volume>:<fpage>10</fpage><pub-id pub-id-type="doi">10.3389/fendo.2014.00010</pub-id><pub-id pub-id-type="pmid">24550888</pub-id></mixed-citation>
      </ref>
      <ref id="B99">
        <label>99</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ning</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2</article-title>. <source>J Biol Chem</source> (<year>2013</year>) <volume>288</volume>:<fpage>24590</fpage>&#x2013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.467837</pub-id><pub-id pub-id-type="pmid">23861392</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>